May 13: The FDA approved Lenvima (lenvatinib) in combination with everolimus to treat advanced renal cell carcinoma after antiangiogenic therapy. The agency first approved the Eisai Co., Ltd. capsule in February 2015 for the treatment of differentiated thyroid cancer that has progressed after radioactive iodine therapy (SPN 3/15, p. 11). Novartis Pharmaceuticals Corp.’s everolimus is […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.